ram; (f) Sertraline. Table S1: Displaying commence and cease positions applied to extract relevant genetic data from complete UKB sample. Table S2: Frequencies of CCR8 Agonist list CYP2C19 diplo-types and metabolic phenotypes in 33,149 Biobank participants taking antidepressants or antipsychotics. Table S3: Frequencies of CYP2D6 diplo-types and metabolic phenotypes in 33,149 Biobank participants taking antidepressants or antipsychotics. Table S4: HbA1c levels and CYP phenotypes across individual and groups of medications. Table S5: Characteristics of CYP2C19 metabolic phenotype in our sample. Table S6: Characteristics of CYP2D6 metabolic phenotype in our sample. Table S7: CYP2D6 metabolic phenotypes of folks taking antidepressants. Table S8: CYP2C19 metabolic phenotypes of persons taking antidepressants. Table S9: CYP2D6 metabolic phenotype of individuals taking antipsychotics. Table S10: Association between CYP2D6 metabolic phenotype and HbA1c within people taking paroxetine–Additional detail. Table S11: Association in between CYP2D6 metabolic phenotype and HbA1c inside people taking fluoxetine–additional detail. Table S12: Association amongst CYP2D6 metabolic phenotype and HbA1c inside people taking venlafaxine–additional detail. Table S13: Association in between CYP2C19 metabolic phenotype and HbA1c within folks taking citalopram. Table S14: Stratified evaluation of people today taking citalopram. Table S15: Association involving CYP2C19 metabolic phenotype and HbA1c inside folks taking sertraline. Table S16: Stratified analysis of men and women taking sertraline. Table S17: Association in between CYP2D6 and CYP2C19 metabolic phenotype and HbA1c within Amitriptyline. Table S18: Stratified analysis of persons taking amitriptyline. Table S19: Association involving CYP2D6 and CYP2C19 metabolic phenotype and HbA1c inside folks taking tricyclic antidepressants. Table S20: Stratified analysis of folks taking tricyclic antidepressants. Table S21: Antipsychotics regression model. Association in between CYP2D6 metabolic phenotype and HbA1c–additional detail. Table S22: Association between CYP2D6 metabolic phenotype and HbA1c amongst participants taking only antipsychotics, devoid of a co-prescribed antidepressant. Author Contributions: Conceptualization, I.A.-Z., M.W. and E.B.; methodology, I.A.-Z., M.W., H.I. and E.B.; formal analysis, I.A.-Z., M.W., H.I.; investigation, I.A.-Z., M.W., H.I.; information curation, I.A.-Z., S.D., G.F., C.F. and J.H.-S.; writing–original draft preparation, I.A.-Z. and M.W.; writing–review and editing, All; visualization, I.A.-Z.; supervision, I.A.-Z., A.M. and E.B.; project administration, I.A.-Z., A.M. and E.B.; funding CDK2 Inhibitor Gene ID acquisition, I.A.-Z., A.M. and E.B. All authors have study and agreed to the published version from the manuscript. Funding: This study was supported by Healthcare Investigation Council doctoral studentships awarded to Isabelle Austin-Zimmerman, Anjali Bhat, and Jasmine Harju-Sepp en. Baihan Wang was supported by the China Scholarship Council-University College London Joint Analysis Scholarship. Haritz Irizar has received funding from the European Union’s Horizon 220 investigation and innovation programme un-der the Marie Sklodowska-Curie grant agreement no 747429 and is presently supported by a grant from the National Institute of Allergy and Infectious Ailments, National Institutes of Wellness. Spiros Denaxas is supported by the NIHR Biomedical Investigation Centre at University College London Hospital NHS Trust, an Alan Turing Fellowship (EP/N51012